Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00313391 · ClinicalTrials.gov registry record · Phase 4
Risperdal Consta and Health Care Utilization in Patients With Schizophrenia
A Phase 4 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 4
- Development phase
NCT00313391 is a Phase 4 study that has completed, run by Emory University.
The verdict
NCT00313391, a Phase 4 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
Study Summary
The purpose of this study is to determine if Risperdal Consta will affect the healthcare utilization costs in chronically ill schizophrenic patients with multiple admissions to the psychiatric hospital compared to the previous utilization costs under standard oral treatment of any atypical antipsychotic. We hypothesize that higher Risperdal Consta acquisition costs can be offset by reduction in total medical utilization costs, such as hospitalizations, ER visits, unscheduled outpatient visits or incarcerations due to worsening of psychotic symptoms.
Interventions
- DRUG Risperdal Consta
Trial Details
| Field | Value |
|---|---|
| Start Date | 2005-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00313391
The ClinicalTrials.gov registry entry for NCT00313391 describes a study currently listed as completed, categorized as Phase 4. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Risperdal Consta is the first listed.
NCT00313391 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00313391 about?
NCT00313391 is a clinical study titled "Risperdal Consta and Health Care Utilization in Patients With Schizophrenia". The purpose of this study is to determine if Risperdal Consta will affect the healthcare utilization costs in chronically ill schizophrenic patients with multiple admissions to the psychiatric hospital compared to the previous utilization costs under standard oral treatment of any atypical antipsych...
What is the current status of trial NCT00313391?
This trial is currently completed. It is a Phase 4 study. The study started on 2005-12.
What interventions are being tested in trial NCT00313391?
The interventions under investigation include: Risperdal Consta (DRUG).
Who is sponsoring clinical trial NCT00313391?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.